A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity

A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0721-8060 in Healthy Adult Participants Living With Overweight or Obesity

The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.

Inclusion Criteria:

• Male or female (sex at birth).
• Age 18-55 years (both inclusive) at the time of signing informed consent.
• Body Mass Index (BMI) 27.0-34.9 kilograms per square metre (kg/m^2) (both inclusive) at screening, with overweight due to excess adipose tissue as judged by the investigator.
• Considered eligible based on medical history, physical examination, vital signs, electrocardiogram and clinical laboratory tests at screening, as judged by the investigator.

Exclusion Criteria:

• Known or suspected hypersensitivity to study intervention(s) or related products.
• Previous randomisation in this study.
• History of allergies (with the exception of seasonal allergies) or history of anaphylactic reactions.
• Female who is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not using adequate contraception.
• Current participation (signed informed consent) in any other interventional clinical study.
• Exposure to an investigational medicinal product within 30 days or five half-lives of that product (whichever is longer) before screening.
• Any disorder, unwillingness or inability which, in the investigator's opinion, might jeopardise participant safety or compliance with the protocol.
• Glycated haemoglobin (HbA1c) greater than or equal to (≥) 6.5 percentage (%) (48 millimoles per mole [mmol/mol]) at screening.